<DOC>
	<DOC>NCT00744263</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.</brief_summary>
	<brief_title>Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Pneumonia, Pneumococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female adults aged 65 years or older on the day of vaccination and able to fulfill study requirements. Previous vaccination with any licensed or experimental pneumococcal vaccine Residence in a nursing home, longterm care facility, or similar facility Known hypersensitivity to vaccination Immune deficiency or suppression</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>